Aerie Pharmaceuticals — Investor Presentation (July 2019)
20 slides from Aerie Pharmaceuticals's investor presentation, Jul 23, 2019

Slide 1: Company Overview Investor Presentation July 2019
Company Overview Investor Presentation July 2019 Exhibit 99.1

Slide 2: Disclaimer and forward-looking statements
The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by reference to repor

Slide 3: Aerie Overview
For Investor Use Aerie Overview Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA. Additional potential Rhopressa® indications are being considered for further study and are not labeled indications. AR-13503 and AR-1105 are pre-clinical molecules and hav

Slide 4: Glaucoma Market Perspective
For Investor Use Glaucoma Market Perspective - ~$3B Market, 35M TRx, 52M bottles - Half of volume first-line (PGAs) - Half of volume 2-3X/Day Adjuncts 2018 U.S. Glaucoma Market Graph Source: IQVIA 2018 CAI: Carbonic Anhydrase Inhibitor AA: Alpha Agonist BB: Beta Blocker Source: IMS/NPA Data R12M May

Slide 5: Rhopressa and Rocklatan Positioning
For Investor Use Rhopressa® and Rocklatan® Positioning HCP’s positioning as concomitant therapy HCP’s positioning as therapy for patients requiring maximal IOP lowering with one drop per day Rhopressa® Positioning Rocklatan® Positioning Efficacy vs. other adjunctive therapies QD PM dose Lack of seri

Slide 6: Rocklatan Month 12 Responder Analysis
For Investor Use Rocklatan® Phase 3 Month 12 Responder Analysis: Goal is to Achieve Lowest IOP Possible At Month 12: % of Patients with IOP Reduced to 18 mmHg or Lower *p<0.05, **p<0.01, ***p<0.0001 ++Data on File Based on Mercury 1 Interim Analysis 2 Rocklatan® has not been approved by any regulato

Slide 7: U.S. Glaucoma Franchise Launch Update
For Investor Use U.S. Glaucoma Franchise Launch Update Actual Sales-Out to Pharmacies data as of 7/19/19 IQVIA data as of 7/12/19 Actual bottles dispensed exceed Rx’s due to extended supply plans (e.g., 90 days’ supply) Rhopressa® and Rocklatan® have not been approved by any regulatory authority oth

Slide 8: Gaining Market Access
For Investor Use Gaining Market Access Access percentages reflect signed contracts, not necessarily implemented underlying formulary coverage. Rhopressa® Access as of July 2019: Commercial ~ 90% Medicare Part D ~ 75% Rocklatan® Expected Access by end of September 2019: Commercial ~ 75% (Rhopressa® ~

Slide 9: Launch Considerations
For Investor Use Launch Considerations Aerie is in the unique position of gaining coverage for Rocklatan® while continuing to grow Rhopressa® Underlying formulary coverage is sometimes delayed Physicians are navigating through the treatment paradigm to optimize patient care while considering patient

Slide 10: Active Engagement at Key Conferences
For Investor Use Active Engagement at Key Conferences March 2019: American Glaucoma Society (AGS) April/May 2019: Association of Research in Vision and Ophthalmology (ARVO) May 2019: American Society of Cataract and Refractive Surgeons (ASCRS) July 2019: American Society for Retina Specialists (ASRS

Slide 11: Expanding Aerie Franchise: Europe
For Investor Use Expanding Aerie Franchise: Europe MAA accepted for Rhokiinsa® (Rhopressa®) in October 2018, regulatory decision expected by end of 2019 Mercury 3: 6-month safety and 90-day efficacy registration trial comparing Rocklatan® (known as Roclanda® in Europe) for non-inferiority to a fixed

Slide 12: Expanding Aerie Franchise: Japan
For Investor Use Expanding Aerie Franchise: Japan Advancing clinical development on our own, established branch office in Tokyo Phase 1 completed; successful Pilot Phase 2 completed in the U.S. on Japanese and Japanese-Americans; Phase 2 commenced in Japan, enrollment completed July 2019 Phase 2 Stu

Slide 13: Advancing the Pipeline
Advancing the Pipeline Drug/Target Indication Development Stage Discovery Preclinical Phase 1/2a AR-1105 Implant (Dexamethasone) RVO AR-13503 Implant (ROCK, PKC) wAMD DME/DR Glaucoma Neuro- enhancement AR-xxxxx Implant (ROCK/JAK/IKK) Dry AMD/GA AR-xxxxx (JAK, IKKb) Dry Eye/MGD AR-xxxxx (ROCK, JAK, I

Slide 14: Retinal Eye Diseases – Aerie's Next Chapter
For Investor Use Retinal Eye Diseases – Aerie’s Next Chapter Bringing Small Molecule Therapy to Back of the Eye Most retinal drugs in use and in pipeline are protein therapeutics Longer half-life allows monthly to bimonthly IVT injections Protein therapeutics address limited number of extracellular

Slide 15: 2018 U.S. Retinal Disease Market
For Investor Use 2018 U.S. Retinal Disease Market 2018 Sales: $6.0B 2018 Unit Sales: 7.3MM Sources: Mixture of public information, IQVIA, Market-Scope and estimates – March 2019

Slide 16: Aerie's Innovation in Retinal Disease
For Investor Use Aerie’s Innovation in Retinal Disease Small Molecule Drug Candidates Proprietary Drug Delivery Technology Bio-erodible, sustained-release implant for intravitreal injection DSM PEA Polymer PLGA PRINT® Mfg AMD DME RVO Dry AMD/GA Glaucoma Others Aerie Kinase Library Non-Aerie drug can

Slide 17: Retinal Eye Disease: Unmet Needs in AMD and DME
For Investor Use Retinal Eye Disease: Unmet Needs in AMD and DME Need new treatments to address disease mechanisms beyond VEGF Complex pathology cannot be addressed by a single drug class Anti-VEGFs are used to treat the eye with wet AMD, while the second eye typically has dry AMD and a high risk of

Slide 18: Aerie's Lead Retina Product Candidates
For Investor Use Aerie’s Lead Retina Product Candidates AR-1105 (Dexamethasone) Implant Indications: retinal vein occlusion (RVO) and DME Target product profile vs. Ozurdex® Longer duration of efficacy (6 mo vs 3 mo) Improved administration due to smaller needle Potential for fewer adverse effects d

Slide 19: AR-13503 Synergistic to Eylea in Mouse Model of PDR
For Investor Use AR-13503 Synergistic to Eylea® in Mouse Model of Proliferative Diabetic Retinopathy Oxygen-induced retinopathy (OIR) mouse model - PDR -40% * Administration: Intraperitoneal QD * : p<0.01 *** : p<0.0001 -60% % of Total Area Neovascular Area (+SEM) Data on File Sub-optimal dose level

Slide 20: Summary Key Priorities
For Investor Use Summary Key Priorities Rhopressa®: Continued successful launch execution Rocklatan®: Successful launch execution Globalization Strategy Europe/Japan clinical path and commercialization strategy Ireland Manufacturing Facility Research Initiatives Rhopressa® normal tension glaucoma, p
Source: SEC EDGAR · 8-K filed Jul 23, 2019
More decks from Aerie Pharmaceuticals Inc.
Investor Presentation (September 2022)30 slides · Sep 13, 2022
Merger or Acquisition (August 2022)30 slides · Aug 23, 2022
Investor Presentation (June 2022)30 slides · Jun 8, 2022
Investor Presentation (May 2022)28 slides · May 25, 2022
Investor Presentation (April 2022)25 slides · Apr 11, 2022
Investor Presentation (January 2022)33 slides · Jan 5, 2022